<p>Presented are treatment groups (A) Control, (B) irradiation (IR), (C) gemcitabine (GEM) and (D) combination gemcitabine and irradiation (GEM+IR). Data is presented over the first week of the study as the mean ± SEM.</p
<p>Cohort II: Percent of Targeted Dose (relative to targeted dose at start of treatment)for patients...
<p>Left panels of (A) and (B) indicate bright field (BF) images and right panels indicate fluorescen...
<p>The median tumor ADC increased in both cases (therapy: 0.72×10<sup>−3</sup> mm<sup>2</sup>/s to 0...
<p>*Treatment Groups, number of animals at the start of the study and the number of animals survivin...
<p>The volume ratio of the tumor was obtained from the initial volume (V<sub>0</sub>) at the onset o...
<p>(A) Treatment schedule schematic for <i>Study 2</i>. Animals were randomized into four groups: co...
<p>(A) Tumor volumes and (B) ADC of mice in three treatment groups were shown at each time point fro...
<p>A. Tumor volume (mm<sup>3</sup>) for each individual mouse, as measured from T<sub>2</sub>W MRI i...
<p>(A) Volume changes of tumors sensitive, intermediate, or resistant to tamoxifen over 32 days afte...
<p>(A) Tumor volumes plotted over time (p-values in legend show significance versus controls at day ...
<p>(A) The tumor volume curve during treatment. Arrows indicate the time of injection. The day when ...
<p>Plots of <b>(a)</b> the mean ADC change and <b>(b)</b> the percentage of voxels with significantl...
<p>Tumor size initially and after 8 weeks of treatment with ascorbic acid, gemcitabine, and erlotini...
<p>OMB significantly improve RT outcome, whereas NMB as controls do not (n = 6 per group). Box-and-w...
<p>Box plots show the distribution of mean pretreatment ADC values (A) and percentage change in ADC ...
<p>Cohort II: Percent of Targeted Dose (relative to targeted dose at start of treatment)for patients...
<p>Left panels of (A) and (B) indicate bright field (BF) images and right panels indicate fluorescen...
<p>The median tumor ADC increased in both cases (therapy: 0.72×10<sup>−3</sup> mm<sup>2</sup>/s to 0...
<p>*Treatment Groups, number of animals at the start of the study and the number of animals survivin...
<p>The volume ratio of the tumor was obtained from the initial volume (V<sub>0</sub>) at the onset o...
<p>(A) Treatment schedule schematic for <i>Study 2</i>. Animals were randomized into four groups: co...
<p>(A) Tumor volumes and (B) ADC of mice in three treatment groups were shown at each time point fro...
<p>A. Tumor volume (mm<sup>3</sup>) for each individual mouse, as measured from T<sub>2</sub>W MRI i...
<p>(A) Volume changes of tumors sensitive, intermediate, or resistant to tamoxifen over 32 days afte...
<p>(A) Tumor volumes plotted over time (p-values in legend show significance versus controls at day ...
<p>(A) The tumor volume curve during treatment. Arrows indicate the time of injection. The day when ...
<p>Plots of <b>(a)</b> the mean ADC change and <b>(b)</b> the percentage of voxels with significantl...
<p>Tumor size initially and after 8 weeks of treatment with ascorbic acid, gemcitabine, and erlotini...
<p>OMB significantly improve RT outcome, whereas NMB as controls do not (n = 6 per group). Box-and-w...
<p>Box plots show the distribution of mean pretreatment ADC values (A) and percentage change in ADC ...
<p>Cohort II: Percent of Targeted Dose (relative to targeted dose at start of treatment)for patients...
<p>Left panels of (A) and (B) indicate bright field (BF) images and right panels indicate fluorescen...
<p>The median tumor ADC increased in both cases (therapy: 0.72×10<sup>−3</sup> mm<sup>2</sup>/s to 0...